Showing 2941-2950 of 2974 results for "".
Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicDr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatHolding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-frontline-treatment-approach-for-stage-iv-braf-wild-type-melanoma/15436/How can we make an informed decision on which target combined with a PD-1 inhibitor provides the most benefit in patients with metastatic melanoma?Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/Are you as excited as our experts are about immunotherapy for the adjuvant treatment of stage IIB/IIC melanoma? Tune in to find out why you should be!DermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiAD Impact, Allofill Comes to Market, GPA Launches
https://practicaldermatology.com/topics/psoriasis/dermwiretv-ad-impact-allofill-comes-to-market-gpa-launches/18567/From sleep disruptions or negative impact on the ability to work to feelings of depression and anxiety, atopic dermatitis can have significant effects on adults, new research suggests. In fact, more than half of respondents to a Harris Poll say that AD has negatively impacted their daily lives. DoriPruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
https://practicaldermatology.com/programs/cme/pruritus-cases-from-the-field-real-world-perspectives-on-managing-ckd-ap/14969/Did you know that many patients on dialysis suffer from itch, or pruritus? Hear patients describe their experiences with a new FDA-approved therapy.Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
https://practicaldermatology.com/programs/cme/targeting-il-13-in-moderate-to-severe-atopic-dermatitis-forging-a-new-path-to-improved-disease-and-patient-outcomes/16384/Get expert insights on incorporating novel agents to optimize care for patients with atopic dermatitis, including those targeting interleukin (IL)-13.Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
https://practicaldermatology.com/programs/cme/directed-relief-in-ckd-ap-linking-targeted-therapy-to-clinical-outcomes/14967/Join our experts’ discussion to learn how to significantly improve quality of life for your patients with chronic kidney disease-associated pruritus.Eczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, and